• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Denali inks collab with Takeda to help Alzheimer’s drugs get into the brain

January 5, 2018 By Sarah Faulkner

Denali TherapeuticsDenali Therapeutics (NSDQ:DNLI) has landed a strategic partnership with Takeda Pharmaceutical (TYO:4502) to develop and commercialize three of its product candidates for neurodegenerative diseases.

The deal includes Denali’s preclinical Alzheimer’s projects, among other undisclosed candidates, which make use of the company’s antibody transport vehicles, or ATVs, to penetrate the blood-brain barrier.

According to the terms of the deal, Takeda is slated to make an initial payment of $150 million through a combo of upfront payments and purchase of Denali equity. Denali could also receive development and commercial milestone payments, including $90 million in preclinical milestones.

Denali is responsible for development activities and costs prior to filing an IND for the three programs, the companies reported. Takeda retains the option to co-develop and co-commercialize the three programs and if it chooses to do so, the companies will jointly conduct clinical development and share the costs.

Takeda and Denali plan to jointly commercialize products in the U.S. and China, but Takeda has exclusive commercialization rights in all other markets. The two companies will share global profits equally, they reported.

“This partnership further exemplifies Takeda’s continued commitment to developing genetically validated therapies for neurodegenerative diseases through an enhanced portfolio comprised of new modalities,” Emiliangelo Ratti, head of Takeda’s neuroscience therapy area, said in prepared remarks. “We are excited to partner with the Denali team, whose innovative technology is uniquely poised to deliver the next generation of antibody therapeutics for patients.”

“We are impressed with Takeda’s commitment to developing treatments for difficult to treat neurodegenerative diseases and look forward to partnering with them to bring medicines to patients,” Denali CEO Ryan Watts added. “Takeda has a great track record of partnering with biotech firms in addition to unique development expertise and a strong global commercial presence.”

DNLI shares were up 3.5% in mid-morning activity, trading at $16.64 apiece.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Neurological, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: denalitherapeutics, Takeda Pharmaceutical Co

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS